Forty patients with immature, non-vital maxillary incisors were included in this study from the outpatient clinic of the Faculty of Dentistry, Ain Shams University, Cairo, Egypt. A detailed medical and dental history was obtained from each patient's parents or guardians. Only medically free patients were included in this research. The clinical and radiographic exclusion criteria were teeth with vertical fractures, periodontally involved teeth, and nonrestorable teeth. All procedures were performed after obtaining proper institutional review board approval based on the regulations of the Ethical Committee of the Faculty of Dentistry, Ain Shams University (FDASU-RECID011508). Intraoral periapical radiographs revealed immature apices. The age of the patients ranged between 8 and 18 years. Informed consent was signed for Abstract Introduction: The aim of this clinical study was to evaluate the effect of different antibacterial combinations on the outcome of revascularization process in permanent anterior immature teeth.Methods: Immature necrotic permanent maxillary incisors (n = 40) of patients 8-18 years old were divided into 4 groups according to the intracanal medicament: group 1 was treated with Triple Antibiotic Paste (TAP), group 2 was treated with Ciprofl oxacin + Propolis paste (CP), group 3 was treated with Ciprofl oxacin + Metronidazole paste (CM), group 4 was treated with Propolis + Metronidazole paste (PM). Cases were followed at regular intervals up to 18 months clinically and radiographically.Results: All cases showed radiographic evidence of periapical healing and continued root development. No statistically signifi cant difference in root length, thickness, apical closure or periapical density between all groups through the whole follow up period. Conclusion:Propolis is successful substitute for ciprofl oxacin or metronidazole in DAP for effective disinfection in revascularization process.
Objective: This study was established to assess cysteamine’s cytotoxic effect alone and in combination with various intracanal medications on fibroblast cells. Because the biocompatibility of intracanal medication is considered one of the main factors that affect the selection of specific medication for usage near vital periodontal tissues. Materials and Methods: All tested medications were prepared in a solution form. Cysteamine preparation was prepared at 200mg/ml concentration in distilled water. Chlorhexidine Cysteamine combination was prepared by dissolving 10 mg/ml of Cysteamine in CHX. Calcium hydroxide Cysteamine combination was prepared by dissolving 10 mg/mL of Cysteamine in a saturated solution of CaOH. TAP Cysteamine combination was prepared by dissolving 10 mg/mL of Cysteamine in TAP. BHK cells were seeded in well-microtiter plates. The testing materials were filtrated using a 0.22 μm syringe filter. BHK-21 cells precultured well plates were treated with descending 12-fold serially diluted medications at 37 °C for 24 h. Residual living cells were treated with 25 μl of MTT dye. MTT was discarded, then Dimethyl sulfoxide was added as 50 μl/well. The absorbance was conducted at 570nm. The mean optical density and 50 % cell growth inhibition (IC50) were calculated. The significance level was set at p≤0.05. Results: Viability % and IC50 results showed that TAP Cysteamine combination had the lowest cytotoxicity level compared to other intracanal combinations followed by Cysteamine and the highest cytotoxicity was with Chlorhexidine Cysteamine combination. Conclusion: TAP Cysteamine combination was the safest drug compared to other drug combinations with cysteamine, so it needs more research to detect its acceptance with stem cells and its effect on defense mechanisms during healing.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.